– UK, Macclesfield – BiVictriX Therapeutics plc (LON: BVX), a biotechnology company developing next-generation cancer therapies, today announced the appointment of Non-Executive Director Dr. Michael Kauffman (M.D., Ph.D.) as the Non-Executive Chairman, succeeding Iain Ross, who will remain on the Board as Non-Executive Director.
“I am delighted to welcome Michael to his new role; no doubt his wealth of expertise across oncology drug development will continue to prove invaluable during the next stage of our progression,” said CEO, Tiffany Thorn.
About Dr. Michael Kauffman
Before becoming Non-Executive Chairman, Dr. Kauffman was appointed as Non-Executive Director of BiVictriX in January 2022. He is a highly experienced cancer drug developer, having been instrumental in the approval of several oncology therapeutics over twenty years of working across preclinical research, clinical development, regulatory strategy, and commercialisation. As Non-Executive Chairman, he will draw upon his previous experience as Co-Founder and CEO of oncology company Karyopharm Therapeutics Inc., which he guided from a discovery stage biotechnology company to a commercial-stage organisation, with global approvals of XPOVIO. He also led the Kyprolis® development program at Proteolix and then Onyx Pharmaceuticals, the Velcade® development program at Millennium Pharmaceuticals, and has held several senior positions at Millennium Predictive Medicine and Biogen. Dr. Kauffman currently holds other Non-Executive Board positions at Verastem Oncology, Adicet Bio, and Kezar Life Sciences.
Dr. Michael Kauffman commented: “Having been a member of BiVictriX’s Board over the past year, I have witnessed the Company’s remarkable progress and am excited to step up to Chairman at this stage of the Company’s development. The Bi-Cygni® platform is designed to optimize the potential of ADCs by reducing off-target-binding associated with toxicities and increasing tumor-selective killing. I am looking forward to BiVictriX progressing BVX001 into the clinic, where we hope to be differentiated by our delivery of key outcomes in cancer-selective therapies for the support of patients who currently have limited options.”
About BiVictriX Therapeutics plc
BiVictriX is a UK-based drug discovery and development company focused on leveraging clinical experience to develop a new class of highly selective, next-generation cancer therapeutics that exhibit superior potency, whilst significantly reducing treatment-related harmful side effects.
The Company utilizes a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® therapeutics designed to selectively target cancer-specific antigen pairs, or “twin antigens fingerprints”, on tumor cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of hematological cancers, it has not yet been widely used in a therapeutic setting, where it offers the opportunity to be a game-changing approach to cancer care.
BiVictriX has identified a diverse panel of novel cancer-specific “twin antigens fingerprints” across a broad range of cancer indications. The Company is using these novel twin antigens to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.
For more information: https://www.bivictrix.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
